Image Name - Referrals for Clinicians
(opens in new tab)

How We Work With Healthcare Providers

How We Work With Healthcare Providers

Patients are best served when the all members of the provider/clinical team work together and are fully informed. We value your expertise and welcome the opportunity to support you and your patients.

Submit your referral
Image Name - Referrals for Clinicians

We Work With:

  • Psychiatrists
  • Therapists
  • Psychologists
  • Neurologists
  • Pain Specialists
  • Primary Care Physicians
  • Coaches
  • Social Workers

Treatments for:

  • Depression
  • Anxiety
  • PTSD
  • Migraines & Headaches
  • CRPS & Chronic Pain
  • Immunity & Resilience

Our Services:

  • IV Ketamine
  • Spravato (intranasal Ketamine)
  • Stellate Ganglion Blocks (SGB)
  • IV Nutrients & Vitamins
  • IV NAD+
  • IV Glutathione
  • Ketamine Assisted Psychotherapy (KAP)
  • Life Skills Coaching

Let us help you support your patients!

We pride ourselves on offering our patients a process that is administratively efficient and clinically rigorous while maintining a high level of personalized care and attention.

Step 1: Confirm Your Patient's Interest

The first step is to confirm your patient's openness/interest in infusion therapies such as Ketamine, NAD+, Vitamins, Glutathione, etc. by having a conversation with the differences between Combination Infusion Therapy and conventional approaches to treating anxiety, depression and PTSD.

Step 2: Submit Online Patient Referral Form

If you believe your patient may be a good fit for guided Ketamine treatments, then please tell us a little about them so we may contact them. You can submit a Patient Referral Form here.

Step 3: Review Patient Care Plan With Us

Once we have spoken with your patient and received required documents, we will contact you to confirm/discuss our treatment plan. We value your input and experience and will work closely with you to ensure the best patient care possible.

Step 4: We Provide Ongoing Updates About Treatments and Progress

With your patient's consent, we will share treatment information with you in order to keep you informed of their progress.

Research Papers

Augmenting the Treatment of PTSD with Ketamine—a Review

May 10, 2019

Or Duek, Benjamin Kelmendi, Robert H. Pietrzak & Ilan Harpaz-Rotem  Published 10 May 2019 | […]

Ketamine as Treatment for Post-Traumatic Stress Disorder: A Review

April 8, 2019

Off-label and novel treatments continue to be considered for more refractory and disabling cases of PTSD. Ketamine is one such treatment that has been discussed and utilized more often for treatment-resistant major depressive disorder (MDD).

Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial

March 29, 2019

Jennifer L. Phillips, Ph.D., Sandhaya Norris, M.D., Jeanne Talbot, M.D., Ph.D., Meagan Birmingham, M.A., M.B.A., […]

Ketamine Assisted Psychotherapy (KAP): Demographics, Data, & Outcomes

March 27, 2019

Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has

Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials

March 13, 2019

Orhurhu, Vwaire MD, MPH; Orhurhu, Mariam Salisu MD, MPH; Bhatia, Anuj MD, FRCPC; Cohen, Steven […]

Ketamine: A Paradigm Shift for Depression Research and Treatment

March 6, 2019

John H. Krystal, Chadi G. Abdallah, Gerard Sanacora, Dennis S. Charney, Ronald S. Duman Published […]

Ketamine for Treatment-Resistant Mood Disorders

January 7, 2019

Strong evidence supports the rapid, although temporary, antidepressant effects of a single intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and bipolar depression.

Magnesium And Ketamine In The Treatment Of Depression

January 6, 2019

Magnesium and ketamine have a common mechanism of action in the treatment of depression: an increase in GluN2B (NMDAR subunit) expression is related to the administration of both of the agents, as well as inhibition of phosphorylation of eEF2 (eukaryotic elongation factor 2) in cell culture and increase of the expression of BDNF in the hippocampus.

Scroll to Top